Published in J Pharm Sci on December 01, 2004
Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci (2009) 1.18
Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII). J Pharm Sci (2005) 0.96
Role of partial protein unfolding in alcohol-induced protein aggregation. Proteins (2010) 0.85
Mechanisms of m-cresol-induced protein aggregation studied using a model protein cytochrome c. J Pharm Sci (2011) 0.82
Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability. Biochemistry (2009) 0.80
Structural and thermodynamic effects of ANS binding to human interleukin-1 receptor antagonist. Protein Sci (2008) 0.80
High-pressure studies of aggregation of recombinant human interleukin-1 receptor antagonist: thermodynamics, kinetics, and application to accelerated formulation studies. Protein Sci (2005) 0.79
Effect of antimicrobial preservatives on partial protein unfolding and aggregation. J Pharm Sci (2012) 0.78
Prevention of benzyl alcohol-induced aggregation of chymotrypsinogen by PEGylation. J Pharm Pharmacol (2011) 0.77
Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease. BMC Pharmacol Toxicol (2015) 0.77
Role of benzyl alcohol in the unfolding and aggregation of interferon α-2a. J Pharm Sci (2014) 0.76
Antimicrobial preservatives induce aggregation of interferon alpha-2a: the order in which preservatives induce protein aggregation is independent of the protein. Int J Pharm (2014) 0.75
Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus (2017) 0.75
Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res (2003) 4.01
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci (2009) 2.36
Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci (2006) 1.60
Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci (2003) 1.51
High-molecular-weight aggregates in repackaged bevacizumab. Retina (2010) 1.45
IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci (2009) 1.41
Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci (2005) 1.33
Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry (2003) 1.27
Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci (2007) 1.27
Rescue of cystathionine beta-synthase (CBS) mutants with chemical chaperones: purification and characterization of eight CBS mutant enzymes. J Biol Chem (2010) 1.20
Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci (2009) 1.18
Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci (2011) 1.17
Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng (2009) 1.17
Thermal stability of vaccines. J Pharm Sci (2003) 1.17
Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci (2010) 1.16
Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci (2008) 1.16
BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems. J Pharm Sci (2006) 1.11
Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci (2009) 1.10
Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J Biol Chem (2003) 1.10
Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci (2009) 1.10
Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem (2012) 1.09
Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci (2010) 1.08
Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation. J Pharm Sci (2005) 1.08
Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. Biochemistry (2002) 1.07
Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions. J Pharm Sci (2010) 1.05
Sedimentation velocity analytical ultracentrifugation and SEDFIT/c(s): limits of quantitation for a monoclonal antibody system. Anal Biochem (2006) 1.04
Peptide cysteine thiyl radicals abstract hydrogen atoms from surrounding amino acids: the photolysis of a cystine containing model peptide. J Phys Chem B (2008) 1.04
Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1. J Biol Chem (2006) 1.03
Effects of sucrose on conformational equilibria and fluctuations within the native-state ensemble of proteins. Protein Sci (2003) 1.02
Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying. J Pharm Sci (2008) 1.01
Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations. J Pharm Sci (2002) 1.00
Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. J Pharm Sci (2012) 1.00
Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J Pharm Sci (2008) 0.98
Rational design of stable lyophilized protein formulations: theory and practice. Pharm Biotechnol (2002) 0.98
Effects of solutes on solubilization and refolding of proteins from inclusion bodies with high hydrostatic pressure. Protein Sci (2005) 0.98
Solid state chemistry of proteins: II. The correlation of storage stability of freeze-dried human growth hormone (hGH) with structure and dynamics in the glassy solid. J Pharm Sci (2008) 0.98
Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. J Pharm Sci (2009) 0.98
Reversible intramolecular hydrogen transfer between protein cysteine thiyl radicals and alpha C-H bonds in insulin: control of selectivity by secondary structure. J Phys Chem B (2008) 0.97
Aggregation of a monoclonal antibody induced by adsorption to stainless steel. Biotechnol Bioeng (2010) 0.97
Ligand-induced conformational and structural dynamics changes in Escherichia coli cyclic AMP receptor protein. Biochemistry (2002) 0.96
Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci (2006) 0.96
Kinetics and energetics of assembly, nucleation, and growth of aggregates and fibrils for an amyloidogenic protein. Insights into transition states from pressure, temperature, and co-solute studies. J Biol Chem (2002) 0.96
Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci (2009) 0.96
The stability factor: importance in formulation development. Curr Pharm Biotechnol (2002) 0.95
Common excipients impair detection of protein aggregates during sedimentation velocity analytical ultracentrifugation. J Pharm Sci (2009) 0.95
High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. J Pharm Sci (2008) 0.95
Protein instability following transport or storage on dry ice. Nat Methods (2013) 0.94
Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci (2011) 0.94
Oxidation of methionine residues in recombinant human interleukin-1 receptor antagonist: implications of conformational stability on protein oxidation kinetics. Biochemistry (2007) 0.93
Cryopreservation of stem cells using trehalose: evaluation of the method using a human hematopoietic cell line. Stem Cells Dev (2004) 0.93
Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. J Pharm Sci (2011) 0.92
High hydrostatic pressure as a tool to study protein aggregation and amyloidosis. Biochim Biophys Acta (2002) 0.92
Protein formulation and fill-finish operations. Biotechnol Annu Rev (2002) 0.92
Effects of surfaces and leachables on the stability of biopharmaceuticals. J Pharm Sci (2011) 0.91